Triple-negative breast cancer (TNBC) represents approximately 15–20% of all breast carcinomas and is defined by the absence of immunohistochemical expression of estrogen receptor (ER) and progesterone receptor (PR), as well as the lack of HER2 protein overexpression or HER2 gene amplification [1]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.